Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | ACHE | P22303 | 3/20 | 0.31 |
| ▸ | CHRNE | Q04844 | 1/20 | 0.31 |
| ▸ | EDNRA | P25101 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3813409 | 0.85 | TLR7 (0.46) | CA2 | |
| SCHEMBL3820918 | 0.83 | TLR7 (0.42) | — | |
| SCHEMBL3813387 | 0.82 | TLR7 (0.38) | — | |
| SCHEMBL3823319 | 0.81 | FUCA1 (0.46) | HTR1A | |
| SCHEMBL3814421 | 0.79 | HTR1A (0.33) | HTR1AACHECHRNE | |
| SCHEMBL727204 | 0.77 | KDM4E (0.31) | — | |
| SCHEMBL5746870 | 0.74 | BCHE (0.35) | HTR1AACHECHRNE | |
| SCHEMBL727247 | 0.74 | CA1 (0.33) | HTR1ACA2 | |
| SCHEMBL14516489 | 0.71 | HTR7 (0.47) | HTR1AACHE | |
| SCHEMBL14516490 | 0.70 | TLR7 (0.41) | CA2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1642580-B1 | Sulfonamide substituted imidazoquinolines | COLEY PHARM GROUP INC (US) | 2009-08-19 | — | — | EP | claimed |
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | 3M INNOVATIVE PROPERTIES COMPANY | 2004-02-12 | — | — | US | claimed |
| US-6331539-B1 | INDUCE BIOSYNTHESIS OF INTERFERON ALPHA IN ANIMALS | 3M INNOVATIVE PROPERTIES COMPANY | 2001-12-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029877-A1 | Sulfonamide and sulfamide substituted imidazoquinolines | IFNG, IRF3, EIF2AK2 | HTR1A 4332/4885CA2 2521/4885ACHE 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.